`Combating Generics 2008: Counter-Generics Strategy, Tactics and Execution' A Candid Study Available Now

Business Wire, Nov 15, 2007

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c74255) has announced the addition of Combating Generics 2008: Counter-Generics Strategy, Tactics and Execution to their offering.

Protect brand revenues with a multi-tiered counter-generics strategy:

Generic drugs now account for more than 60% of all prescriptions filled in the US, and more than $60 billion worth of drugs face US patent expiration by 2011.

Use this report to build a counter-generics strategy that includes long-term, R&D-based lifecycle planning (such as new formulations and next-generation drugs) as well as frontline tactics (such as litigation and counter-promotion) -- and understand how companies launch authorized generics and attempt OTC switches

Explore primary data for a comprehensive look at current counter-generics defense:

- Investigate strategies, investments and results for seven brands

- Benchmark your efforts against timelines, investment levels, and past-and-future use of critical lifecycle management and counter-generics options:

New formulation launches

Defensive pricing changes

Counter-promotion

Approval for new indications

Next-generation product launches

Patent litigation

Authorized generics negotiations

Launches through generics subsidiaries

Pediatric trials and six-month exclusivity

OTC switching

- Compare headcounts dedicated to counter-generics preparation over the life of a brand

Charts and Graphics:

EXECUTIVE SUMMARY

Figure E.1: Generic Entry Following Patent Expiration

Figure E.2: Market Share Erosion Following Patent Expiration

Combating Generics: Five Principles for Success

Figure E.3: Generics Defense Planning Begins (Relative to Product Age)

Figure E.4: Functions Contributing to Counter-Generics Defense

COUNTER-GENERICS TACTICS, TIMING AND RESOURCES

Figure 1.1: Counter-generics Planning Begins (Relative to Product Age)

A Matter of Timing: Developing and Implementing a Strategy

Figure 1.2: Counter-generics Planning Begins (Relative to Patent Expiration)

Trends in the Prevalence of Counter-Generics Tactics

Figure 1.3: Historical Data: Prevalence of Counter-Generics Strategies, 2004-2006

Figure 1.4: Prevalence of Counter-Generics Strategies, 2005-2007

Figure 1.5: Anticipated Counter-Generics Strategies, 2008-2010

Figure 1.6: Changes in Counter-Generics Strategy

Figure 1.7: Functions Contributing to Counter-Generics Defense Staffing Resources

Figure 1.8: Counter-Generics Headcounts Over Time

Brand Strategy Profiles

Figure 1.9: Brand A' s Counter-Generics Strategy

Figure 1.10: Brand B' s Counter-Generics Strategy

Figure 1.11: Brand C' s Counter-Generics Strategy

Figure 1.12: Brand D' s Counter-Generics Strategy

Figure 1.13: Brand E' s Counter-Generics Strategy

Figure 1.14: Brand F' s Counter-Generics Strategy

Figure 1.15: Brand G' s Counter-Generics Strategy

FRONTLINE COUNTER-GENERICS TACTICS

Patent Litigation

Figure 2.1: Prominence of Patent Litigation

Figure 2.2: Use of Litigation (Relative to Patent Expiration)

Figure 2.3: Time To Execute Litigation

Figure 2.4: Investment in Litigation

Figure 2.5: Prominence of Citizen Petitions

Filing Citizen Petitions

Figure 2.6: Use of Citizen Petition (Relative to Patent Expiration)

Figure 2.7: Time to Execute Citizen Petition

Figure 2.8: Prominence of Pediatric Exclusivity

Pediatric Exclusivity

Figure 2.9: Use of Pediatric Exclusivity (Relative to Patent Expiration)

Figure 2.10: Time To Execute Pediatric Exclusivity

Figure 2.11: Falling Approval Rates: Requests for Pediatric Exclusivity Trials

Figure 2.12: Prominence of Defensive Pricing

Defensive Pricing

Figure 2.13: Investment in Defensive Pricing

Figure 2.14: Time to Execute Defensive Pricing

Figure 2.15: Use of Defensive Pricing (Relevant to Patent Expiration)

Figure 2.16: Zocor Sales, 2003-2006

Figure 2.17: Use of Counter-Promotion (Relative to Patent Expiration)

Counter-Promotion

Figure 2.18: Time To Execute Counter-Promotion

Figure 2.19: Investment in Counter-Promotion

LIFECYCLE MANAGEMENT AND LINE EXTENSIONS

Figure 3.1: Prevalence of Line Extension Strategies, 2005-2007

New Formulations

Figure 3.2: Prevalence of Counter-Generics Strategies, 2005-2007

Figure 3.3: Prominence of New Formulations

Figure 3.4: Use of New Formulation (Relative to Patent Expiration)

Figure 3.5: Time to Execute New Formulation

Figure 3.6: Investment in New Formulation

Figure 3.7: Glucophage Franchise Sales, 2000-2004

Figure 3.8: Prominence of New Indications

New Indications

Figure 3.9: Use of New Indication

Figure 3.10: Time to Execute New Indication

Figure 3.11: Investment in New Indication

Next-Generation Products

Figure 3.12: Prominence of Next-Generation Products

Figure 3.13: Time to Execute Next-Generation Drug

Figure 3.14: Use of Next-Generation Drug (Relative to Patent Expiration)

Figure 3.15: Investment in Next-Generation Drug

Figure 3.16: Transitioning Prilosec to Nexium

Figure 3.17: Claritin/Clarinex Sales, 1999-2005

Figure 3.18: Forest Laboratories' Antidepressant Franchise

Combination Therapies

Figure 3.19: Prominence of Combination Products

Figure 3.20: Historical Data: Prevalence of Counter-Generics Strategies, 2004-2006